Sierra Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Vancouver, BC CAN
Total Funding:N/A
Industry:Biotech
Founded:N/A
Lead Investor(s):Silicon Valley Bank

Industry Ranking

Estimated Revenue & Financials

  • Sierra Oncology's estimated annual revenue is currently $9.8M per year.
  • Sierra Oncology received $15.0M in venture funding in August 2018.
  • Sierra Oncology's estimated revenue per employee is $119,085

Employee Data

  • Sierra Oncology has 82 Employees.
  • Sierra Oncology grew their employee count by -4% last year.
  • Sierra Oncology currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$8.7M56-11%N/A-N/A
#2
$2.2M14N/AN/A-N/A
#3
$301.3M1944N/AN/A-N/A
#4
$32.2M208N/AN/A-N/A
#5
$15.5M100N/AN/A-N/A
#6
$17.1M110N/AN/A-N/A
#7
$9.8M82-4%N/A-N/A
#8
$20.6M133N/AN/A-N/A
#9
$31M200223%N/A-N/A
#10
$7.3M47104%N/A-N/A
Missing a competitor? Contribute!?
Submit

Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737's potential to induce synthetic lethality as monotherapy, while the SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. We are also advancing SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). SRA141 is currently undergoing preclinical research in preparation for an Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA).

keywords:N/A

82

Number of Employees

$9.8M

Revenue (est)

1

Current Jobs

-4%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Sierra Oncology News

12-Sep-19 - Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?

The big shareholder groups in Sierra Oncology, Inc. (NASDAQ:SRRA) have power over the company. Institutions will often hold stock in bigger ...

12-Sep-19 - What has caused a significant move in Sierra Oncology, Inc. (SRRA)?

Sierra Oncology, Inc. (NASDAQ:SRRA) is a stock to watch today. At current price of $0.44, the shares have already added 0.03 points (7% ...

12-Sep-19 - Sierra Oncology Inc. (SRRA)'s Financial Results Comparing With uniQure NV (NASDAQ:QURE)

As Biotechnology businesses, Sierra Oncology Inc. (NASDAQ:SRRA) and uniQure N.V. (NASDAQ:QURE), are affected by compare.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$20.8M829%N/A-N/A
#2
$18.8M83N/AN/A-N/A
#3
$12M8384%$71M4.4/5N/A
#4
$29.3M8315%N/A-N/A
#5
$19.2M849%N/A-N/A

Sierra Oncology Funding

DateAmountRoundLead InvestorsReference
2005-10-20$4.2MUndisclosedApjohn Ventures, Grand AnglesArticle
2006-10-25$6.6MUndisclosedMultipleArticle
2014-01-02$11.2MUndisclosedArticle
2014-01-14$12.0MCArticle
2014-04-22$59.5MDMultipleArticle
2017-02-09$UndisclosedUndisclosedJefferies LLCArticle
2018-03-05$49.2MUndisclosedJefferiesArticle
2018-08-23$15.0MUndisclosedSilicon Valley BankArticle

Sierra Oncology Executive Hires

DateNameTitleReference
2014-09-04Nick GloverPresident/CEOArticle
2015-12-04Keith AndersonSVP Technical OperationsArticle
2016-06-02Christian HassigSVP ResearchArticle